Call toll-free 800.328.1267

Insights AI

The market’s most important stocks, simplified

Hims & Hers Health Inc. reported mixed financial results for Q3 2025, with earnings per share (EPS) of $0.06, missing the $0.09 analyst estimate, but revenue of $598.97 million exceeded the $580.24 million forecast. The company achieved a 21% year-over-year increase in its subscriber base, reaching nearly 2.5 million. For fiscal 2025, Hims & Hers narrowed its revenue outlook to $2.335 billion–$2.355 billion, aligning with the $2.341 billion analyst estimate. However, its Q4 revenue projection of $605 million–$625 million fell short of the $631.68 million consensus estimate. The company is expanding its Hers platform to address perimenopause and menopause care, potentially increasing its market size and supporting its goal of surpassing $1 billion in annual revenue by 2026. Discussions to add Novo Nordisk's Wegovy products could further enhance its weight-loss treatment offerings. Despite these growth initiatives, concerns remain over its valuation, trading at 64-times forward earnings and nearly five-times trailing-year sales, as well as its high debt-to-equity ratio of 1.86. While revenue and subscriber growth are promising, these factors, along with a cautious revenue outlook, may weigh on investor sentiment.
Source content provided by Benzinga.
This content was created in whole or in part using Generative Artificial Intelligence (AI). Please read the disclosures found at the end of this content for more information.

Ready to make your move?

You’ve seen the news. It’s time to set your strategy. The TradeStation ecosystem is designed to execute your trades no matter how unique or complex. Set your strategy in motion with the advanced tools and brokerage services built specifically for those who are born to trade

Recent news for HIMS

News in this section is provided by Benzinga and is written entirely by Benzinga authors. Articles are presented as they were provided by Benzinga, and do not represent the opinions of TradeStation or its employees.

By clicking one of the links below, you are leaving TradeStation.com.

Looking For A Squeeze? Top 10 Most Shorted Stocks Right Now

Here's a look at the top 10 most shorted stocks in the market right now, including Lucid, MARA, Kohl's and more.

What's Going On With Shares Of Hims & Hers Health Thursday?

Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international expansion.

Hims & Hers Snaps Up YourBio To Bring Pain-Free Blood Tests Home

Hims & Hers agrees to acquire YourBio Health, adding painless microneedle blood-sampling tech and expanding its at-home testing capabilities ahead of an early-2026 close.

About HIMS

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include ... Read more

Ways to trade options* on HIMS

Bearish Option Strategy: Long Puts

Traders buy a single put option on a stock or ETF. This strategy can benefit from a price drop while risking more capital than a spread.

Learn more

  • 1
  • 2
  • 3

Insights AI filters through the noise to uncover meaningful data that natural-born traders can use to find new trading opportunities. Our AI model distills complex market news and data into accessible, actionable intelligence. Stay informed of market moves with curated trading intelligence and platform tips delivered directly to you.

Market Insights, Insights AI, and all related pages and content are hosted by TradeStation Group, Inc.

The symbols selected include stocks that meet a specific set of criteria: the 50 most active stocks based on 21-day options volume. ETFs and meme stocks are not included.

This Content was created in whole or in part using Generative Artificial Intelligence (AI). While efforts have been made to ensure accuracy, the Content is generated autonomously by AI algorithms and it may contain errors or inaccuracies. Users are advised to critically evaluate the information presented.

This Content is for educational and informational purposes only. Any symbols or trading strategies discussed are for demonstration purposes only and are not research or recommendations.

TradeStation Group, Inc. (“TradeStation”) pays third parties for the data and other information included on this page (the “Content”). The Content is derived from news and other information feeds provided by Accretive Capital LLC d/b/a Benzinga (“Benzinga”) and market activity. Benzinga is not affiliated with TradeStation. TradeStation makes the Content available for informational purposes only. The Content should not be considered an offer or solicitation tobuy, sell, or hold any investment/security. The Content is believed to be from reliable sources; however, TradeStation does not verify all of the information included in the Content for accuracy or completeness. TradeStation does not endorse any third-party content, and any views or opinions expressed in the Content do not necessarily represent the views and opinions of TradeStation. Any goods or services offered by Benzinga are not sponsored, endorsed, sold, or promoted by TradeStation, and TradeStation makes no representation regarding any such goods or services.

TradeStation does not endorse or adopt the Content, and makes no guarantees that the Content is accurate, complete, or timely. TradeStation assumes no responsibility for the accuracy, completeness, updates, changes, or timeliness of the Content. TradeStation does not provide investment, tax or legal advice. Any recommendation, opinion or advice regarding securities or markets contained in the Content does not reflect the views of TradeStation. TradeStation assumes no responsibility for any fact, recommendation, opinion or advice contained in the Content and expressly disclaims any responsibility for any decisions based upon any such Content.

Any decisions you may make to buy, sell or hold a security or other investment based on the Content or other third-party information will be entirely your own and not in any way deemed to be endorsed, influenced by or attributed to TradeStation. It is understood that, without exception, any order based on the Content that is placed with TradeStation for execution should be considered by you to be an unrecommended and unsolicited order. TradeStation will treat all such orders as unsolicited.

*Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com/DisclosureOptions. Visit www.TradeStation.com/Pricing for full detailson the costs and fees associated with options.